BMS Temporarily Transfers Allergy Drug Pemilaston To Alfresa Pharma
This article was originally published in PharmAsia News
Executive Summary
U.S. drugmaker Bristol-Myers Squibb announced Nov. 26 that the company has transferred manufacturing and marketing rights of allergy drug Pemilaston (pemirolast) in Japan to Alfresa Pharma until the end of March 2009. A subsidiary of Alfresa Holdings, Alfresa Pharma has been focusing on allergy drugs and pemirolast will strengthen its product lineup, while Bristol is consolidating resources on its cancer and HIV drug business. (Click here for more - Japanese language